BELANOFF JOSEPH K 4
4 · CORCEPT THERAPEUTICS INC · Filed Aug 5, 2025
Insider Transaction Report
Form 4
BELANOFF JOSEPH K
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-08-01$68.87/sh−17,809$1,226,486→ 2,866,816 total(indirect: By Trust) - Sale
Common Stock
2025-08-01$69.65/sh−5,446$379,305→ 2,861,370 total(indirect: By Trust) - Sale
Common Stock
2025-08-01$67.81/sh−16,745$1,135,416→ 2,884,625 total(indirect: By Trust)
Footnotes (5)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
- [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.42 to $68.33 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F3]Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
- [F4]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.43 to $69.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F5]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.4412 to $69.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.